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Vitamin D Receptor Gene 
Polymorphisms Modify 
Cardiometabolic Response to 
Vitamin D Supplementation in 
T2DM Patients
Nasser M. Al-Daghri  1,2, Abdul Khader Mohammed1,2, Omar S. Al-Attas1,2, Mohammed 
Ghouse Ahmed Ansari  1,2, Kaiser Wani1,2, Syed D. Hussain1, Shaun Sabico1, Gyanendra 
Tripathi3 & Majed S. Alokail1,2
There is conflicting evidence on the favorable effects of vitamin D supplementation on metabolic profile 
in Type 2 diabetes mellitus (T2DM) patients and this might be due to genetic variations in vitamin D 
receptors (VDRs). Thus, we studied the metabolic effects of a 12-month vitamin D supplementation in 
T2DM patients according to VDR polymorphisms. A total of 204 T2DM subjects received 2000 IU vitamin 
D3 daily for 12 months. Serum 25(OH)D and metabolic profiles were measured at baseline and after 12 
months. VDR polymorphisms (Taq-I, Bsm-I, Apa-I and Fok-I) were identified using TaqMan genotyping 
assays. Vitamin D supplementation significantly increased HOMA β-cell function (p = 0.003) as well 
as significantly decreased triglycerides, total and LDL-cholesterol (p < 0.001). The lowest increment 
in 25(OH)D levels was detected in patients with Fok-I CC genotypes (p < 0.0001). With vitamin D 
supplementation, Taq-I GG genotype carriers showed significant improvements in triglycerides, LDL- 
and total cholesterol, insulin, HbA1c and HOMA-IR (p < 0.005, 0.01, < 0.001, < 0.005, 0.03 and 0.01, 
respectively). Similarly, Bsm-I TT genotype carriers showed significant improvements in triglycerides 
(p = 0.01), insulin and HOMA-IR (p-values < 0.05). In conclusion, improvements in metabolic profile due 
to vitamin D supplementation is influenced by VDR polymorphisms, specifically for carriers of Taq-I GG 
and Bsm-I TT genotypes.
Vitamin D plays a crucial role in calcium homeostasis and bone metabolism. Over the past decade, extra-skeletal 
effects of vitamin D has attracted considerable interest, including type 2 diabetes mellitus (T2DM)1, 2. In vitro 
studies showed that the active form of vitamin D (1,25-dihydroxyvitamin D or 1,25(OH)2D3) stimulates the 
release of insulin by the pancreatic β-cells3, 4. Numerous observational and epidemiological studies also reported 
an inverse association between serum 25-hydroxy vitamin D (25(OH)D) levels and fasting glucose, insulin resist-
ance and lipid profile excluding HDL-cholesterol5–10. Despite promising results in favor of vitamin D, interven-
tional studies yielded divergent results. Recent systematic reviews of randomized control trials (RCTs) in T2DM 
patients suggest an insufficient evidence about the beneficial effects of vitamin D supplementation on glucose 
homeostasis or insulin resistance11, 12. Similarly, some RCTs failed to indicate an association between vitamin D 
supplementation and a favorable lipid profile13, 14. In contrast, other studies have reported that vitamin D supple-
mentation improved lipid profile and insulin sensitivity15–18. Differences in responses to vitamin D supplementa-
tion may partially be explained by the genetic makeup and variations involved in vitamin D pathway19. Vitamin 
D receptor (VDR) gene is one such factor responsible for regulating responses to vitamin D. It is known that the 
active form of vitamin D (1,25 (OH)2D3) binds with the cytosolic/nuclear VDR which then heterodimerizes 
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with retinoid X receptor and regulates expression of several target genes20. In fact, VDR is expressed in a variety 
of tissues including muscles and pancreatic cells21, 22.
Several single nucleotide polymorphisms (SNPs) have been identified in the VDR gene including Taq-I, 
Bsm-I, and Apa-I polymorphisms, which are located at the 3′ untranslated region (3′ UTR) of the gene and are 
suspected to alter VDR expression23, 24. While another polymorphism known with Fok-I restriction site is located 
within the 5′ end near the promoter region23. Fok-I is a functional polymorphism that results in different trans-
lation initiation sites on VDR that lead to three amino acids becoming longer and less effective protein25. Since 
these polymorphisms affect the stability and activity of VDR mRNA and protein, it is likely that the individuals 
who are not responding cardiometabolically to vitamin D treatment might be due to these VDR SNPs. Indeed, 
recent studies have reported that the VDR genotypes may potentially affect the individual’s response to treatment. 
For instance, women with the VDR Bsm-I CC genotype had greater improvement in bone mineral density after 
treatment than those with the TT genotype26. Likewise, in patients with benign prostate hyperplasia, response to 
standard drug therapy is significantly associated with the VDR Taq-I genotype27.
There is limited information regarding the cardiometabolic effects of vitamin D intake based on VDR gene 
polymorphisms in T2DM subjects. The only study by Neyestani et al.19 have shown that subjects with VDR Fok-I 
ff genotype responded the least to vitamin D-fortified yogurt intake in terms of improvement serum 25(OH)D 
levels and some inflammatory markers. Given the potential of other VDR SNPs (Taq-I, Bsm-I, Apa-I) to influence 
the stability of VDR mRNA herein, we aim to evaluate the effects of vitamin D supplementation according to four 
different VDR SNPs (Taq-I, Bsm-I, Apa-I and Fok-I) on glycemic and lipid responses in T2DM patients. For this 
study, 204 T2DM patients who were mostly vitamin D deficient were enrolled and given 2000 IU vitamin D daily 
for 12 months, and screened for four different VDR SNPs (Taq-I, Bsm-I, Apa-I and Fok-I).
Results
Improved glycemic and lipid profile after 12 months of vitamin D supplementation. Table 1 
shows the differences between baseline and 12-months supplementation in the studied subjects. There was 
a significant increase in serum 25(OH)D levels from baseline to12 months after vitamin D supplementation 
(p < 0.001). Improved serum 25(OH)D levels had a parallel significant decrease in LDL- total cholesterol 
(p < 0.0001) as well as triglycerides (p < 0.001) (Table 1). There was also a significant increase in serum insulin 
(p < 0.005) and HOMA-β cell function (p < 0.003).
Effect of VDR genotypes on anthropometric and clinical parameters after vitamin D supple-
mentation. Prevalence of vitamin D sufficiency (serum 25(OH)D > 50 nmol/L) increased after 12 months 
of vitamin D supplementation. However, around 42.2% of the subjects remained vitamin D deficient (Fig. 1). To 
explore whether VDR genotype has any influence on determining the vitamin D status (Deficiency/Sufficiency), 
subjects were compared according to VDR genotype. At baseline, there was no significant trend in distribution 
of vitamin D deficiency status among VDR Fok-I variants (P-trend = 0.626). However, after intervention, trend 
test was highly significant (P-trend < 0·0001), showing > 51% of subjects with Fok-I TC genotype and almost all 
subjects with CC genotype remained vitamin D deficient (Table 2). Further data analysis indicates that after 12 
months of vitamin D supplementation, subjects in Fok-I TT group showed better improvement (increased) in 
serum 25(OH)D levels compared to CC group (TT 24.4 ± 15.8 vs CC 8.4 ± 9.6; p < 0.001) (Table 3 and Fig. 2). 
This association remained significant (p = 0.005) even after adjusting for confounders such as age, gender, BMI 
N = 204 Baseline Follow-up p value
BMI (kg/m2) 32.3 ± 5.9 32.5 ± 6.0 0.008
Waist Circumference (cm) 106.2 ± 12.9 106.2 ± 12.9 0.843
Hips Circumference (cm) 110.9 ± 12.9 111.6 ± 13.7 0.112
Waist-Hip Ratio 1.0 ± 0.1 1.0 ± 0.1 0.581
Systolic Blood Pressure 
(mmHg) 127.0 ± 15.1 127.2 ± 14.5 0.897
Diastolic Blood Pressure 
(mmHg) 80.1 ± 9.2 79.2 ± 9.5 0.355
Triglycerides (mmol/l) 2.0 ± 0.8 1.9 ± 0.8 0.037
Total Cholesterol (mmol/l) 5.3 ± 1.1 4.9 ± 1.1 0.0001
HDL-Cholesterol (mmol/l) 1.0 ± 0.3 0.9 ± 0.3 0.0001
LDL-Cholesterol 3.3 ± 0.9 3.0 ± 1.0 0.0001
Fasting Glucose (mmol/l) 10.6 ± 4.6 10.7 ± 4.5 0.974
Insulin (uU/ml) # 15.8 ± 9.8 18.5 ± 12.0 0.005
HbA1c 7.5 ± 2.3 7.7 ± 2.5 0.274
HOMA-IR # 8.1 ± 7.9 8.7 ± 7.8 0.187
HOMA β-cell function # 60.3 ± 61.2 72.0 ± 67.4 0.003
25(OH)D (nmol/l) 33.4 ± 12.2 54.2 ± 17.6 0.0001
Table 1. Anthropometrics and biochemical characteristics of all T2DM subjects at baseline and after 12 months 
of vitamin D supplementation. Note: Data were presented as mean ± standard deviation. # log-transformed 
prior to analysis. BMI- Body mass index; HOMA-IR- Homeostasis model assessment for insulin resistance.
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and baseline 25(OH)D levels. After Bonferroni correction, this association remained significant (P = 0.02). In 
addition, subjects with the rare Fok-I CC genotype also showed significant increase in BMI (1.0 ± 1.4 kg/m2, 
p = 0.02) compared to TT and TC genotypes, after 12 months of vitamin D supplementation (Table 3).
Next, we compared the changes in glycemic and lipid profile according to VDR genotypes after intervention. 
Subjects with Taq-I GG genotype group showed significantly better improvements in glucose and lipid profile 
than other genotypes. A significant decrease in total cholesterol (−0.9 ± 0.9 mmol/l, p < 0.001), LDL-cholesterol 
(−0.7 ± 1.1, p = 0.01), triglycerides (−0.4 ± 0.5, p < 0.005), insulin (−2.3 ± 12.0 uU/ml, p < 0.005), HbA1c 
(p = 0.03) and HOMA-IR (p = 0.01) were observed in subjects with GG genotype than subjects with AA and 
AG genotypes (Table 4). However, significance for LDL-cholesterol (p = 0.09) and HOMA-IR (0.08) disappeared 
after adjustments for age, gender, BMI and baseline vitamin D levels. Associations of Taq-I genotypes with tri-
glycerides, total-cholesterol, insulin and HbA1C remained significant after Bonferroni correction. Similarly, 
subjects carrying Bsm-I CC genotypes had better improvements in triglycerides (−0.4 ± 0.5, p = 0.01), insulin 
(−2.0 ± 11.7 uU/ml, p = 0.01) and HOMA-IR (p = 0.05) than other genotypes (Table 5). However, significance 
for HOMA-IR disappeared after adjustment with confounding factors. Likewise, subjects carrying Apa-I hete-
rozygous AC genotype showed significantly better improvement in systolic blood pressure (−4.3 ± 14.5 mmHg, 
p = 0.009) than with AA and CC genotypes (Table 6).
Haplotype and linkage disequilibrium (LD) analysis. VDR gene polymorphisms at Taq-I were in LD 
with both Bsm-I and Apa-I (R2 = 0.87 and −0.44 respectively). In addition, Bsm-I and ApaI SNPs were also in 
LD with each other (R2 = −0.61) (Supplementary Table S1). As there was a strong positive LD between Taq-I 
and Bsm-I SNPs, indicating two alleles occurred on the same haplotype more than expected. Thus, we com-
bined the different genotypes from Taq-I and Bsm-I to check the haplotype effect on various parameters. After 12 
months of vitamin D supplementation, Taq-IGG + Bsm-ITT haplotype showed significantly higher decrease in 
total cholesterol (−0.8 ± 0.9; p = 0.015), glucose (−1.3 ± 3.6; p = 0.036), insulin (−2.3 ± 12.0; p = 0.010), triglyc-
erides (−0.4 ± 0.5; p = 0.012), HbA1c (−0.7 ± 2.3; p = 0.03) and HOMA-IR (−1.6 ± 5.5; p = 0.024) compared to 
Taq-IAA + Bsm-ICC and Taq-IAG + Bsm-ICG (Supplementary Table S2).
Disscussion
The present study showed varying degrees of metabolic improvements from vitamin D supplementation, partly 
due to variability in the VDR gene. In patients with Fok-I CC genotypic group, improvement in serum 25(OH)
D levels was the least compared to other Fok-I genotypic groups, implying that VDR gene polymorphisms might 
be crucial for vitamin D intervention. Intake of 2000 IU/D vitamin D has beneficial effects on glycemic and lipid 
profile, but these effects were more pronounced in patients with Taq-I GG and Bsm-I TT genotypes in VDR gene.
Figure 1. Comparison of the vitamin D status before and after 12 months of vitamin D supplementation. 
Deficiency: Serum 25(OH)D level < 50 nmol/L. Sufficiency: Serum 25(OH)D level ≥ 50 nmol/L. Desirable: 




TT (N = 113) TC (70) CC (16)
Baseline Follow-up Baseline Follow-up Baseline Follow-up
Desirable 0 (0.0) 14 (12.4) 1 (1.4) 9 (12.9) 0 (0.0) 0 (0.0)
Sufficiency 10 (8.8) 66 (58.4) 4 (5.7) 25 (35.7) 1 (6.3) 1 (6.3)
Deficiency 103 (91.2) 33 (29.2) 65 (92.9) 36 (51.4) 15 (93.8) 15 (93.8)
Table 2. Vitamin D status among the Fok-I genotypic groups before and after 12 months of vitamin D 
supplementation. Note: Σ2 test showed a Ptrend of 0.626 at baseline; Ptrend at 12-month follow-up is < 0.0001. 
Data is presented as frequencies (%). Deficiency: Serum 25(OH)D level < 50 nmol/l. Sufficiency: Serum 25(OH)
D level between 50 to 75 nmol/l. Desirable: Serum 25(OH)D level > 75 nmol/l.
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In the present study, 42.2% of the subjects were not able to achieve the desirable 25(OH)D levels (>50 nmol/L) 
despite a year-long supplementation. In a RCT on obese T2DM Emirati participants, receiving high doses vita-
min D3 was not sufficient to achieve target serum 25(OH)D levels (≥75 nmol/L)28. In a pilot study on American 
subjects randomized to 800 IU/d of supplemental vitamin D, only 50% of the participants reached the desirable 
serum 25(OH)D levels29. Moreover, our previous data in Saudi T2DM patients treated with 2000 IU/D of vitamin 
D for 18 months, as much as 22% of subjects remained deficient30. Since genetic analyses was missing in these 
studies, variations in the genes that regulate 25(OH)D levels could be one explanation. To prove this, data from 
the present study indicated an unaltered vitamin deficiency status in subjects belonging to VDR Fok-I CC group. 
Individuals with homozygous major allele Fok-I (TT) had significantly better increase in serum 25(OH)D levels 
than CC genotype. It is likely that causal variant (Fok-I CC) could possibly alter their role in metabolic feedback 
loops or effect the speed at which 25(OH)D is metabolized31. Smolders et al. have reported that 1,25(OH)2D 
limits its own levels and the levels of its precursor 25(OH)D via the VDR and demonstrated that 25(OH)D and 
1,25(OH)2D-hydroxylation is affected by the Fok-I VDR polymorphism32. However, these genotypic variants 
were not associated with baseline 25(OH)D levels in the present study. It can be speculated that Fok-I genotypic 
variants might require a higher threshold 25(OH)D levels to exhibit its feedback effects. Alternatively, this SNP 
may be in linkage disequilibrium with other neighboring functional polymorphisms which are known to affect 




Baseline 32.1 ± 5.9 32.4 ± 6.2 32.5 ± 5.4
0.02 0.01*12 Months 32.4 ± 6.0 32.5 ± 6.2 33.6 ± 5.2
Change 0.2 ± 0.9 0.1 ± 1.1 1.0 ± 1.4aa
Systolic BP (mmHg)
Baseline 126.7 ± 16.0 128.7 ± 13.9 116.0 ± 8.9
0.10 0.0712 Months 127.5 ± 14.6 126.4 ± 14.8 128.0 ± 11.0
Change 0.9 ± 14.9 −2.2 ± 14.1 12.0 ± 11.0
Diastolic BP (mmHg)
Baseline 79.7 ± 8.9 81.8 ± 9.1 70.0 ± 7.1
0.16 0.2612 Months 79.5 ± 8.9 79.1 ± 10.1 76.0 ± 13.4
Change −0.3 ± 11.0 −2.7 ± 9.2 6.0 ± 18.2
Triglycerides (mmol/l)
Baseline 2.0 ± 0.8 1.9 ± 0.8 2.0 ± 1.2
0.49 0.4912 Months 1.8 ± 0.8 1.9 ± 0.9 1.8 ± 0.9
Change −0.1 ± 0.7 0.0 ± 0.7 −0.2 ± 0.7
Total Cholesterol (mmol/l) 
(mmol/l)
Baseline 5.3 ± 1.0 5.4 ± 1.1 5.0 ± 1.1
0.94 0.6312 Months 4.9 ± 1.0 5.0 ± 1.2 4.7 ± 1.0
Change −0.4 ± 0.9 −0.4 ± 1.0 −0.3 ± 1.2
HDL-Cholesterol (mmol/l)
Baseline 1.0 ± 0.3 1.1 ± 0.3 0.9 ± 0.4
0.47 0.1412 Months 0.9 ± 0.3 0.9 ± 0.3 0.9 ± 0.4
Change −0.1 ± 0.3 −0.2 ± 0.3 0.0 ± 0.5
LDL-Cholesterol (nmol/l)
Baseline 3.3 ± 0.8 3.4 ± 1.1 3.0 ± 0.7
0.38 0.5912 Months 3.0 ± 0.9 3.0 ± 1.2 2.9 ± 0.9
Change −0.3 ± 0.9 −0.4 ± 1.0 −0.1 ± 0.8
Glucose (mmol/l)
Baseline 10.1 ± 3.9 11.9 ± 5.1 8.7 ± 5.0
0.33 0.1212 Months 10.5 ± 4.1 11.4 ± 5.1 8.9 ± 3.6
Change 0.4 ± 3.9 −0.6 ± 4.9 0.2 ± 4.4
Insulin (uU/ml)
Baseline 16.1 ± 9.6 15.7 ± 10.2 12.6 ± 9.8
0.15 0.1912 Months 17.9 ± 11.7 18.9 ± 13.0 22.3 ± 5.6
Change 1.8 ± 12.1 3.2 ± 10.6 9.7 ± 11.3
HbA1c
Baseline 7.1 ± 2.1 8.1 ± 2.5 6.0 ± 1.7
0.28 0.2512 Months 7.5 ± 2.4 8.0 ± 2.6 6.8 ± 1.9
Change 0.4 ± 2.2 −0.2 ± 2.7 0.8 ± 2.5
HOMA-IR
Baseline 8.1 ± 8.7 8.3 ± 6.9 4.9 ± 3.0
0.14 0.1412 Months 8.2 ± 8.1 9.4 ± 7.4 10.0 ± 7.4
Change 0.1 ± 5.9 1.0 ± 6.6 5.2 ± 6.3
25(OH)D (nmol/l)
Baseline 33.0 ± 12.4 33.6 ± 12.3 36.0 ± 10.0
0.001 0.005**12 Months 57.4 ± 17.3 51.3 ± 18.4 44.5 ± 9.2
Change 24.4 ± 15.8 17.7 ± 19.1 8.4 ± 9.6a
Table 3. Comparisons of the variables among the Fok-I genotypic before and after 12 months of vitamin D 
supplementation. Note: Change = Follow up − Baseline; p values presented are for the changes in different 
variables after vitamin D supplementation according to Fok-I genotypes; Pa indicates p values after adjusting 
age, gender, BMI and baseline 25(OH)D levels; Superscript “a” indicates significantly different from TT group 
after post hoc analysis; “*” indicates p < 0.05 after Bonferroni correction.
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baseline 25(OH)D levels. Perhaps, there could be different mechanisms that regulate 25(OH)D derived from 
supplementation vs cutaneous synthesis. In agreement with our results, Neyestani et al. reported T2DM patients 
with minor Fok-I ff (corresponds to Fok-I CC in current study) had significantly lower serum 25(OH)D levels 
after daily intake of vitamin D fortified yoghurt19. Similarly, in a randomized double blinded, placebo-controlled 
trial, Yao et al. demonstrated an association between Fok-I G allele and increase in 25(OH)D levels33. Data form 
previous studies and non-genetic factors including age, BMI and baseline 25(OH)D concentrations could influ-
ence vitamin D treatment outcome34, 35. The association between Fok-I genotypes and increase in serum 25(OH)
D levels remained significant even after adjustments of the above mentioned confounding factors, indicating an 
independent association.
Longitudinal studies have indicated an association between elevated serum 25(OH)D levels with lower T2DM 
risk8, 36. However, results from various RCTs have yielded conflicting results. The current study suggests that vita-
min D intake favorably affects insulin sensitivity and lipid profile of T2DM patients. Muñoz-Aguirre et al.15 have 
also reported that in T2DM patients, 4000 IU/D of vitamin D intake may improve serum triglycerides. Similarly, 
Pittas et al. reported that in the elderly people with impaired fasting glucose, vitamin D and calcium supplemen-
tation might attenuate insulin resistance37. On the contrary, a recent systematic review and meta-analysis by Sieda 
et al. involving 35 RCTs concluded no effect of vitamin D supplementation on glucose homeostasis or diabetes 
prevention11. One possible reason for varying results could be the heterogeneity of the studied cohorts and the 
genetic differences among various ethnic groups. Thus, studying the genetic polymorphisms involved in vitamin 
D pathway might elucidate the potential reasons for inconsistent responses to vitamin D supplementation. For 
instance, the frequency of VDR Taq-I GG was 19.2% in the current study, while it was 15.6% in Non-Hispanic 
whites, 7.2% in Non-Hispanic blacks and 4.9% in Mexican-Americans38. Vitamin D modulates the expression of 
target genes upon binding to VDR, thus studying SNPs in VDR gene might provide insightful inter-individual or 
inter-population variability in response to vitamin D supplementation.
VDR affects cholesterol and bile acid synthesis in hepatocytes and serum by controlling expression of genes 
involved in bile acid synthesis39. Results from humans, animals and in vitro studies indicated that vitamin D defi-
ciency increases serum cholesterol levels by reducing VDR activity40. Disruption of the VDR signaling pathway 
is associated with a reduction in pancreatic insulin mRNA levels leading to impairment in oral glucose tolerance 
and reduced insulin secretory capacity in normally fed mice41. Several studies showed a correlation between VDR 
genotypes with risk of obesity, diabetes and metabolic syndrome. However, the information about the effects of 
vitamin D supplementation and VDR genotypes in improving cardiometabolic aspects in T2DM patients are 
limited. In the present study, though we found no significant variance in increment 25(OH)D levels among var-
ious Taq-I and Bsm-I genotypic groups after vitamin supplementation, patients with Taq-I GG showed signifi-
cant decrease in LDL-, total cholesterol, triglycerides and HOMA-IR levels than their counterparts. Importantly, 
except for LDL-cholesterol and HOMA-IR, the association remained significant after Bonferroni adjustments. 
Similarly, patients carrying Bsm-I TT genotypes showed significant differences in LDL-cholesterol and HOMA-IR 
levels than their counterparts with Bsm-I CT and CC genotypes. Hence, despite a similar rise in serum 25(OH)
D levels in all subjects after supplementation, patients carrying Taq-I GG and Bsm-I TT genotypes seem to have 
better improvement in glycemic and lipid parameters. In particular, Bsm-I, Apa-I, and Taq-I RFLPs are located 
near the 3′ UTR region, which is known to be involved in the regulation of mRNA stability. Hypothetically, the 
presence of Taq-I G allele and Bsm-I T allele might be providing better VDR mRNA stability and half-life result-
ing to a higher number of VDRs expressed for a longer time in target cells, thus leading in a better response to 
vitamin D supplementation.
The authors acknowledge several limitations. Findings cannot be generalized since only patients with T2DM 
were included. Other confounders such as lifestyle, non-genetic factors such BMI, type of anti-diabetic drugs 
and duration of diabetes were not accounted. Finally, the present study did not have a control/placebo group and 
therefore bias is likely in the reported changes post intervention.
Figure 2. Box plot showing distribution of serum 25(OH)D levels (nmol/L) before and after vitamin D 
supplementation according to VDR fok-I genotypes.
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Nevertheless, VDR polymorphisms influence metabolic response to vitamin D supplementation. VDR gen-
otypic variations might help identify those who will benefit the most from vitamin D treatment. Least improve-
ment in serum 25(OH)D levels was observed in patients carrying VDR Fok-I CC genotypes and might need 
higher doses of vitamin D than their counterparts in order to achieve sufficient levels. Cardiometabolic improve-
ment was more evident in carriers of Taq-I GG and Bsm-I TT polymorphisms. These carriers may be the better 
responders to vitamin D therapy in terms of improving metabolic profile and a more tailored approach to vitamin 
D intervention is warranted. However, further analyses in other ethnic populations are needed to fully validate 
these findings.
Material and Methods
Subjects. This study is a part of our previously described vitamin D intervention study30. Briefly, a mul-
ti-center, interventional study was setup in the primary health care centers (PHCCs) in Riyadh, Saudi Arabia. 204 
T2DM Saudi adults who were mostly vitamin D deficient [serum 25(OH)D < 50 nmol/l)] (men, N = 90: women, 
N = 114) were given 2000 IU vitamin D3 (Merck Pharma, Germany) daily for 12 months. All subjects answered a 
generalized questionnaire including present and past medical history. They underwent physical examination and 
submitted their written informed consents prior to inclusion. Patients taking multivitamins, calcium, cortisone 




Baseline 32.0 ± 6.3 31.7 ± 5.9 33.5 ± 5.7
0.21 0.1812 Months 32.1 ± 6.2 31.9 ± 6.0 33.9 ± 5.7
Change 0.1 ± 0.9 0.1 ± 1.1 0.4 ± 0.9
Systolic BP (mmHg)
Baseline 128.6 ± 17.3 126.3 ± 14.3 126.9 ± 15.1
0.58 0.3512 Months 130.9 ± 16.8 126.3 ± 13.0 125.2 ± 14.8
Change 2.3 ± 15.4 0.1 ± 15.8 −1.7 ± 11.0
Diastolic BP (mmHg)
Baseline 80.7 ± 10.0 80.0 ± 8.4 79.7 ± 10.2
0.21 0.2012 Months 82.0 ± 9.8 79.3 ± 9.4 76.0 ± 8.8
Change 1.3 ± 11.3 −0.7 ± 11.4 −3.6 ± 8.3
Triglycerides (mmol/l)
Baseline 2.0 ± 0.9 2.0 ± 0.9 1.9 ± 0.8
0.005 0.01*12 Months 1.6 ± 0.9 1.9 ± 0.8 1.9 ± 0.8
Change −0.4 ± 0.5 −0.1 ± 0.7a 0.0 ± 0.7
Total Cholesterol (mmol/l)
Baseline 5.3 ± 1.1 5.5 ± 1.0 5.0 ± 1.1
0.001 0.01*12 Months 4.4 ± 0.9 5.2 ± 1.0 4.9 ± 1.1
Change −0.9 ± 0.9 −0.3 ± 0.9 −0.1 ± 0.9a
HDL-Cholesterol (mmol/l)
Baseline 1.0 ± 0.3 1.0 ± 0.3 1.0 ± 0.3
0.22 0.7112 Months 0.8 ± 0.3 0.9 ± 0.3 1.0 ± 0.3
Change −0.1 ± 0.4 −0.2 ± 0.3 −0.1 ± 0.3
LDL-Cholesterol (nmol/l)
Baseline 3.4 ± 1.0 3.4 ± 0.9 3.1 ± 1.0
0.01 0.0912 Months 2.7 ± 0.8 3.2 ± 1.1 2.9 ± 0.9
Change −0.7 ± 1.1 −0.2 ± 0.9 −0.2 ± 0.8
Glucose (mmol/l)
Baseline 11.0 ± 3.8 10.6 ± 4.6 10.5 ± 5.1
0.06 0.1412 Months 9.8 ± 4.1 10.8 ± 4.5 11.2 ± 4.6
Change −1.2 ± 3.3 0.2 ± 4.5 0.8 ± 4.6
Insulin (uU/ml)
Baseline 19.0 ± 10.2 15.7 ± 9.9 13.4 ± 8.8
0.005 0.01*12 Months 16.7 ± 10.3 19.1 ± 11.8 18.8 ± 13.9
Change −2.3 ± 12.0 3.4 ± 11.4a 5.4 ± 10.3a
HbA1c
Baseline 7.9 ± 2.4 7.2 ± 2.1 7.6 ± 2.5
0.03 0.01*12 Months 7.2 ± 2.8 7.7 ± 2.3 8.0 ± 2.5
Change −0.7 ± 2.2 0.5 ± 2.4a 0.4 ± 2.5a
HOMA-IR
Baseline 9.2 ± 5.5 8.4 ± 9.8 6.6 ± 5.0
0.01 0.0412 Months 7.6 ± 6.5 9.5 ± 8.9 8.4 ± 6.4
Change −1.6 ± 5.5 1.1 ± 6.9 1.9 ± 5.1
25(OH)D (nmol/l)
Baseline 31.9 ± 12.7 34.4 ± 12.6 33.3 ± 10.7
0.56 0.6212 Months 51.2 ± 13.6 54.7 ± 20.2 56.1 ± 15.5
Change 19.2 ± 15.7 20.3 ± 18.9 22.8 ± 15.4
Table 4. Comparisons of the variables among the Taq-I genotypic before and after 12 months of vitamin D 
supplementation. Note: Change = Follow up − Baseline; p values presented are for the changes in different 
variables after vitamin D supplementation according to Taq-I genotypes; Pa indicates p values after adjusting 
age, gender, BMI and baseline 25(OH)D levels; Superscript “a” indicates significantly different from GG group 
after post hoc analysis; “*” indicates p < 0.05 after Bonferroni correction.
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or any other steroids, products with mineral oil, regular antacids, diuretics, phenytoin and phenobarbital medi-
cations, weight-loss drugs, gallbladder or gastrointestinal disorders and liver problems, were excluded as well as 
evidence of metabolic disease (Paget’s disease or osteomalacia), renal stone disease, hyperparathyroidism and 
abnormal levels of calcium, alkaline phosphatase and phosphorous. Ethical approval of the study including all 
methods and experimental protocols were obtained from the Institutional Review Board (IRB) of the College of 
Medicine, King Saud University in Riyadh, Saudi Arabia. All methods were performed in accordance with the 
relevant guidelines and regulations.
Anthropometry and blood withdrawal. After an overnight fast, subjects returned to their respective 
PHCCs for anthropometry and blood withdrawal. Anthropometry included weight, height, hip and waist circum-
ference (cm), systolic and diastolic blood pressure. Body mass index (BMI) was calculated (kg/m2). Blood was 
transferred to a non-heparinized tube for centrifugation. Serum was then aliquoted into plain tubes and stored 
at −20 °C until further use.
Biochemical analysis. Methods for biochemical analysis was described in our previous paper30. In brief, 
fasting glucose and lipid profile were measured using chemical analyzer (Konelab, Finland). Serum 25(OH)D 




Baseline 32.2 ± 6.1 31.4 ± 5.5 34.1 ± 6.3
0.23 0.1712 Months 32.4 ± 6.0 31.5 ± 5.6 34.6 ± 6.2
Change 0.2 ± 0.9 0.1 ± 1.1 0.4 ± 0.9
Systolic BP (mmHg)
Baseline 128.6 ± 17.3 125.5 ± 14.0 128.6 ± 15.6
0.22 0.0912 Months 130.9 ± 16.8 126.6 ± 12.8 124.6 ± 15.3
Change 2.3 ± 15.4 1.0 ± 15.0 −3.9 ± 12.9
Diastolic BP (mmHg)
Baseline 80.7 ± 10.0 79.5 ± 8.4 80.7 ± 10.2
0.07 0.1012 Months 82.0 ± 9.8 79.3 ± 9.3 75.9 ± 8.9
Change 1.3 ± 11.3 −0.2 ± 11.1 −4.8 ± 8.6
Triglycerides (mmol/l)
Baseline 3.2 ± 1.0 3.4 ± 0.9 3.2 ± 1.0
0.01 0.03*12 Months 2.8 ± 0.9 3.2 ± 1.1 2.8 ± 0.9
Change −0.5 ± 1.2 −0.2 ± 0.9a −0.4 ± 0.9
Total Cholesterol (mmol/l)
Baseline 5.2 ± 1.1 5.5 ± 1.0 5.1 ± 1.0
0.27 0.1712 Months 4.6 ± 1.0 5.2 ± 1.0 4.7 ± 1.0
Change −0.6 ± 1.1 −0.3 ± 0.9 −0.4 ± 0.9
HDL-Cholesterol (mmol/l)
Baseline 1.0 ± 0.3 1.0 ± 0.3 1.0 ± 0.3
0.32 0.4412 Months 0.9 ± 0.3 0.9 ± 0.3 0.9 ± 0.3
Change −0.1 ± 0.3 −0.2 ± 0.3 −0.1 ± 0.4
LDL-Cholesterol (nmol/l)
Baseline 2.1 ± 0.8 2.0 ± 0.8 1.9 ± 0.8
0.38 0.3912 Months 1.7 ± 0.9 1.9 ± 0.8 1.8 ± 0.8
Change −0.4 ± 0.5 0.0 ± 0.7 −0.1 ± 0.7
Glucose (mmol/l)
Baseline 11.1 ± 3.7 10.5 ± 4.6 10.6 ± 5.0
0.30 0.4112 Months 10.2 ± 4.2 10.9 ± 4.6 10.7 ± 4.5
Change −0.9 ± 3.7 0.3 ± 4.4 0.1 ± 4.6
Insulin (uU/ml)
Baseline 18.6 ± 10.1 15.7 ± 9.9 13.6 ± 9.0
0.01 0.01*12 Months 16.6 ± 10.0 19.3 ± 11.7 18.7 ± 14.2
Change −2.0 ± 11.7 3.6 ± 11.3a 5.1 ± 10.8a
HbA1c
Baseline 8.0 ± 2.3 7.1 ± 2.2 7.5 ± 2.5
0.06 0.02*12 Months 7.5 ± 2.8 7.7 ± 2.4 7.7 ± 2.5
Change −0.5 ± 2.3 0.6 ± 2.3a 0.2 ± 2.6
HOMA-IR
Baseline 9.0 ± 5.4 8.4 ± 9.8 6.6 ± 5.1
0.05 0.1012 Months 7.7 ± 6.4 9.6 ± 8.9 8.0 ± 6.5
Change −1.2 ± 5.5 1.2 ± 6.9 1.4 ± 5.2
25(OH)D (nmol/l)
Baseline 31.1 ± 14.0 34.5 ± 12.4 33.6 ± 9.8
0.47 0.4112 Months 50.1 ± 14.7 54.6 ± 19.8 56.6 ± 14.9
Change 19.0 ± 15.9 20.2 ± 18.5 23.0 ± 15.9
Table 5. Comparisons of the variables among the Bsm-I genotypic before and after 12 months of vitamin D 
supplementation. Note: Change = Follow up − Baseline; p values presented are for the changes in different 
variables after vitamin D supplementation according to Bsm-I genotypes; Pa indicates p values after adjusting 
age, gender, BMI and baseline 25(OH)D levels; Superscript “a” indicates significantly different from TT group 
after post hoc analysis; “*” indicates p < 0.05 after Bonferroni correction.
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levels were measured using ELISA (IDS Ltd., Boldon Colliery, Tyne & Wear, UK).The inter and intra-assay var-
iabilities were 5.3% and 4.6% respectively.. Serum insulin was measured using multiplex assay kits (LuminexW 
xMAPW Technology platform) (Luminexcorp, Texas). The inter-assay variation was <21% and intra-assay var-
iation was 1.4–7.9%. Vitamin D deficiency was defined as serum 25(OH)D levels < 50 nmol/L. Homeostasis 
model assessment for insulin resistance (HOMA-IR) was calculated as fasting insulin (IU) x fasting glucose 
(mmol/L)/22.5.HOMA-β secretion (%) was calculated as 20 × fasting insulin (IU)/(fastingglucose-3.5).
VDR gene analysis. Genomic DNA was extracted from whole blood using DNeasy blood and tissue 
kit (Qiagen, Hilden, Germany). The DNA purity (260/280ratio) and concentration were measured using a 
Nano-drop spectrophotometer. The four VDR SNPs: Taq-I(rs731236), Bsm-I(rs1544410), Apa-I(rs7975232), and 
Fok-I(rs10735810) were evaluated by allelic discrimination real-time PCR using predesigned TaqMan genotyp-
ing assays (Applied Biosystems, Foster City, CA). The PCR steps comprisedof a hot start at 95 °C for 10 minutes 
followed by 45 cycles of 94 °C for 15 seconds and 60 °C for 1 minute; fluorescence detection occurs at of 60 °C. All 
the genotyping was performed in 10 µl reactions, using TaqMan genotyping mastermix in 96-well plates in an ABI 
7000 instrument (Applied Biosystems).
Five samples were excluded from the analysis due to the failure of genotyping results.
Variables AA (87) AC (84) CC (28) P Value Pa
BMI (kg/m2)
Baseline 33.7 ± 5.6 32.2 ± 6.2 31.9 ± 5.7
0.47 0.5112 Months 34.2 ± 5.4 32.4 ± 6.3 32.1 ± 5.8
Change 0.5 ± 1.0 0.1 ± 0.9 0.2 ± 1.1
Systolic BP (mmHg)
Baseline 126.9 ± 11.8 130.1 ± 16.3 124.1 ± 14.4
0.009 0.001*12 Months 127.7 ± 10.9 125.8 ± 15.4 128.3 ± 14.4
Change 0.8 ± 10.4 −4.3 ± 14.5a 4.2 ± 14.7
Diastolic BP (mmHg)
Baseline 80.8 ± 9.5 81.2 ± 8.9 78.9 ± 9.3
0.05 0.0712 Months 76.2 ± 9.6 78.4 ± 9.1 80.6 ± 9.8
Change −4.6 ± 6.6 −2.7 ± 10.6 1.6 ± 11.3
Triglycerides (mmol/l)
Baseline 1.9 ± 0.7 1.9 ± 0.8 2.0 ± 0.9
0.50 0.9812 Months 1.8 ± 0.8 1.9 ± 0.7 1.8 ± 0.9
Change −0.1 ± 0.7 0.0 ± 0.7 −0.2 ± 0.7
Total Cholesterol (mmol/l)
Baseline 5.1 ± 1.1 5.4 ± 0.9 5.3 ± 1.1
0.99 0.9312 Months 4.7 ± 1.0 5.0 ± 1.1 4.9 ± 1.0
Change −0.4 ± 1.0 −0.4 ± 1.0 −0.4 ± 0.9
HDL-Cholesterol (mmol/l)
Baseline 1.0 ± 0.3 1.0 ± 0.3 1.0 ± 0.3
0.90 0.9812 Months 0.9 ± 0.4 0.9 ± 0.3 0.8 ± 0.3
Change −0.1 ± 0.5 −0.1 ± 0.3 −0.2 ± 0.3
LDL-Cholesterol (nmol/l)
Baseline 3.0 ± 0.9 3.5 ± 0.8 3.2 ± 1.0
0.79 0.7712 Months 2.7 ± 0.9 3.1 ± 1.0 2.9 ± 1.0
Change −0.3 ± 0.7 −0.4 ± 1.0 −0.3 ± 1.0
Glucose (mmol/l)
Baseline 11.0 ± 5.9 10.7 ± 4.3 10.6 ± 4.3
0.69 0.6212 Months 10.4 ± 4.2 10.8 ± 4.6 10.6 ± 4.4
Change −0.6 ± 4.9 0.2 ± 4.7 0.1 ± 3.7
Insulin (uU/ml)
Baseline 14.4 ± 7.0 15.3 ± 10.1 16.8 ± 10.2
0.98 0.8612 Months 17.0 ± 11.6 18.3 ± 13.1 19.1 ± 11.1
Change 2.6 ± 7.9 3.0 ± 11.7 2.3 ± 12.4
HbA1c
Baseline 7.4 ± 2.7 7.4 ± 2.3 7.5 ± 2.2
0.90 0.8312 Months 7.8 ± 2.5 7.6 ± 2.4 7.7 ± 2.6
Change 0.4 ± 3.0 0.2 ± 2.3 0.1 ± 2.4
HOMA-IR
Baseline 6.7 ± 3.5 7.9 ± 6.6 8.7 ± 9.9
0.63 0.6612 Months 6.6 ± 3.4 8.5 ± 7.0 9.7 ± 9.3
Change −0.2 ± 2.9 0.6 ± 6.6 1.0 ± 6.6
25(OH)D (nmol/l)
Baseline 35.1 ± 9.5 35.0 ± 13.6 31.7 ± 11.2
0.97 0.4412 Months 56.2 ± 13.3 55.9 ± 20.3 52.1 ± 16.1
Change 21.1 ± 14.3 20.9 ± 18.2 20.4 ± 17.4
Table 6. Comparisons of the variables among the Apa-I genotypic before and after 12 months of vitamin D 
supplementation. Note: Change = Follow up − Baseline; p values presented are for the changes in different 
variables after vitamin D supplementation according to Apa-I genotypes; Pa indicates p values after adjusting 
age, gender, BMI and baseline 25(OH)D levels; Superscript “a” indicates significantly different from AA group 
after post hoc analysis; “*” indicates p < 0.05 after Bonferroni correction.
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Statistical Analysis. Data was analyzed using SPSS version 21.0, IBM (Armonk, NY, USA). Variables 
are expressed as mean ± standard deviation (SD). Normality assumption of data was tested using 
Kolmogrov-Smirnov test. Non-Gaussian variables were logarithmically transformed. Paired T-test was done to 
compare pre and post supplementation and analysis of variance (ANOVA) to compare genotype groups. Post hoc 
analysis was done using Tukey’s test. Mantel-Haenzsel test (χ2 linear by linear association) for trend for checking 
p-trend. Bonferroni correction was applied to adjust for multiple comparisons among genotypes. Significance 
was set at p < 0.05.
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